TUCSON, Ariz. and CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 20, 2024 — Critical Path Institute (C-Path) and Centogene N.V. (Nasdaq: CNTG) have announced a Memorandum of Understanding (MOU) to collaborate on drug development for lysosomal diseases (LDs). The partnership aims to leverage both organizations’ expertise in genetic and real-world data (RWD) to create effective therapies for LDs and improve the quality of life for those affected.

CENTOGENE, a leader in genomic and multiomic testing services, has amassed a vast real-world integrated multiomic data repository in rare and neurodegenerative diseases. Their Biodatabank contains data from over 850,000 patients across 120 countries, with over 70% of patients being non-European descent. This extensive data set will be invaluable for research and development.

C-Path focuses on identifying barriers to drug development and creating solutions to overcome them. Their Critical Path for Lysosomal Diseases (CPLD) Consortium, established in 2023, brings together stakeholders from various sectors to accelerate drug development for LDs.

The MOU outlines several areas of collaboration between C-Path and CENTOGENE, including:

  • Data Enrichment and Linkage: Enhancing and connecting data for LDs, particularly for Niemann-Pick disease type C, Gaucher disease types 2 and 3, and mucopolysaccharidosis type II.
  • Genetic Testing Services: Providing genetic testing for clinical trials and observational studies.
  • Sample Analysis Reporting: Offering sample analysis reporting services for diagnostics, utilizing predefined NGS sequencing devices and library kits.
  • Access to CENTOGENE Biodatabank: Allowing limited access to the CENTOGENE Biodatabank for analyzing patients from CPLD projects, potentially including data linkage.
  • Joint Cobranding Efforts: Promoting the collaboration on RWD and genetic data in LDs.

“CENTOGENE is dedicated to providing data-driven solutions that accelerate and de-risk drug discovery and development. Our Biodatabank offers precision, advanced analysis, and access that make a significant difference,” said Prof. Peter Bauer, M.D., Chief Medical and Genomic Officer at CENTOGENE. “This partnership with C-Path advances our shared vision of transforming real-world data into life-saving therapeutics for patients globally.”

Krista Casazza, Ph.D., CPLD Scientific Director, emphasized, “This collaboration with CENTOGENE will allow us to combine our expertise and resources to overcome critical barriers in LD research and drug development.”

For more information about the CPLD consortium, please visit .

About Critical Path Institute

Critical Path Institute (C-Path) is an independent, nonprofit organization founded in 2005. It was established as a public-private partnership in response to the . C-Path’s mission is to lead collaborations that advance better treatments for people worldwide. Recognized as a pioneer in accelerating drug development, C-Path has established numerous international consortia, programs and initiatives, including over 1,600 scientists and representatives from government and regulatory agencies, academia, patient organizations, disease foundations and pharmaceutical and biotech companies. With a dedicated team located worldwide, C-Path’s global headquarters is in Tucson, Arizona and C-Path’s Europe subsidiary is headquartered in Amsterdam, Netherlands. For more information, visit 

Critical Path Institute is supported by the Food and Drug Administration (FDA) of the Department of Health and Human Services (HHS) and is 54% funded by the FDA/HHS, totaling $19,436,549, and 46% funded by non-government source(s), totaling $16,373,368. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, FDA/HHS or the U.S. Government.


CENTOGENE’s mission is to provide data-driven, life-changing answers to patients, physicians, and pharma companies for rare and neurodegenerative diseases. We integrate multiomic technologies with the CENTOGENE Biodatabank – providing dimensional analysis to guide the next generation of precision medicine. Our unique approach enables rapid and reliable diagnosis for patients, supports a more precise physician understanding of disease states, and accelerates and de-risks targeted pharma drug discovery, development, and commercialization.

Since our founding in 2006, CENTOGENE has been offering rapid and reliable diagnosis – building a network of approximately 30,000 active physicians. Our ISO, CAP, and CLIA certified multiomic reference laboratories in Germany utilize Phenomic, Genomic, Transcriptomic, Epigenomic, Proteomic, and Metabolomic datasets. This data is captured in our CENTOGENE Biodatabank, with over 850,000 patients represented from over 120 highly diverse countries, over 70% of whom are of non-European descent. To date, the CENTOGENE Biodatabank has contributed to generating novel insights for more than 300 peer-reviewed publications.

By translating our data and expertise into tangible insights, we have supported over 50 collaborations with pharma partners. Together, we accelerate and de-risk drug discovery, development, and commercialization in target and drug screening, clinical development, market access and expansion, as well as offering CENTOGENE Biodata Licenses and Insight Reports to enable a world healed of all rare and neurodegenerative diseases.

To discover more about our products, pipeline, and patient-driven purpose, visit  and follow us on .


Roxan Triolo Olivas

Kissy Black

Melissa Hall
Corporate Communications

Lennart Streibel
Investor Relations